1 citations
,
October 2025 in “Scientific Reports” This study reports that hedgehog pathway inhibitors, sonidegib and vismodegib, showed distinct adverse event patterns in real-world data, suggesting the need for further research to confirm these findings.
1 citations
,
November 2005 in “Dermatologic Surgery” This study found that aminoguanidine induces VEGF mRNA expression in stored hair follicle micrografts and outer root sheath cells, suggesting potential for enhancing growth factor production during storage.
August 2026 in “Women s Health” This preliminary pilot study found that a combined microneedling-assisted Panax ginseng exosome protocol with adjunctive inner gel use led to short-term improvements in patient-reported vulvovaginal symptoms and qualitative improvements in vulvar skin tone, though results are preliminary and based on a small, uncontrolled sample.
November 2022 in “Journal of Investigative Dermatology” Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.
5 citations
,
January 2022 in “Asian Journal of Pharmaceutical and Clinical Research” In this review, the authors highlight that emulgels, a combination of gel and emulsion, provide an effective topical drug delivery system for hydrophobic drugs, offering benefits like controlled release and versatility in treating various dermatological conditions.
The study reported that vismodegib showed significant effectiveness in treating basal cell carcinoma, particularly in patients with Gorlin-Goltz syndrome or locally advanced BCC, but also highlighted substantial side effects, requiring careful management to prevent treatment resistance and maintain remission.
4 citations
,
May 2020 in “Dermatologic Therapy” In this study, a topical lotion containing Redensyl and Sepicontrol A5 demonstrated effectiveness for treating androgenetic alopecia over 24 weeks, with 73.1% of users seeing moderate improvement and notable increases in hair cycle ratios, alongside enhanced quality of life and satisfaction.
37 citations
,
September 2018 in “The Journal of Clinical Endocrinology and Metabolism” This study found that intravaginal testosterone significantly improved sexual satisfaction and reduced dyspareunia in postmenopausal women using aromatase inhibitors, with no effect on urinary incontinence.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This paper discusses ethosomal drug delivery systems, highlighting their improved ability to enhance skin penetration and increase therapeutic effectiveness in treatments like acyclovir for herpes labialis and minoxidil for androgenic alopecia compared to standard formulations.
July 2026 in “International Journal of Drug Delivery Technology” June 2026 in “Journal of Cosmetic Dermatology” This study reported that microneedle-assisted delivery of PEGylated recombinant human fusion collagen significantly improved hair regrowth and density in an androgenetic alopecia mouse model and in a small clinical trial with AGA patients, suggesting potential efficacy and safety for this treatment approach.
20 citations
,
June 2014 in “Pharmaceutical research” This study found that combining Aliaxin® Global Performance with Viscoderm® Skinkò E improved hydration and appearance of nasolabial folds more effectively than using Aliaxin® Global Performance alone.
May 2023 in “Journal of Drugs in Dermatology” This study reported that the novel topical serum REVIVV®, containing a blend of phytochemicals, significantly improved hair growth and reduced shedding in 150 participants with androgenetic alopecia after 8 weeks of use, while also being rated easy to use and prompting plans for continued use.
51 citations
,
May 2010 in “Journal of Drug Targeting” This study found that Transcutol-containing vesicles improved the delivery of minoxidil to deeper skin layers in vitro but did not facilitate its permeation through the skin.
April 2024 in “Bioactive materials” This study found that a microneedle system delivering VEGF and Ritlecitinib improved hair regeneration in mice with androgenetic alopecia, showing faster anagen onset and better hair quality compared to minoxidil.
April 2026 in “Microsystems & Nanoengineering” This study developed HA-gel-dex hydrogels with enhanced ECM-like properties and functionality, showing promise for 3D bioprinting, tissue repair, and as wound dressings due to improved cell interaction, cytocompatibility, antimicrobial synergy, and wound healing in mice compared to traditional ECM bio-inks.
23 citations
,
March 2021 in “Gels” This study found that minoxidil solubilized in gelatin-containing microemulsions resulted in over 5% of the drug remaining in porcine skin, significantly more than the reference gel.
In this study, researchers found that an injectable solution of low-molecular-weight hyaluronic acid and amino acids significantly improved skin rejuvenation and elasticity in the labia majora of post-menopausal women over 12 weeks, with a reported 25% or greater aesthetic improvement and high patient satisfaction.
July 2024 in “Reactions Weekly” This study found that Dex-loaded hyaluronic acid hydrogel microneedles significantly reduced pain in an acute inflammatory visceral pain model without sedation, suggesting a promising and patient-friendly alternative to intravenous delivery.
3 citations
,
January 2000 in “Current Medical Research and Opinion” This research reported that eflornithine HCl 13.9% cream generally has a favorable dermal safety profile for managing unwanted facial hair in women, though it can cause mild irritation under certain conditions.
November 2024 in “Journal of Cosmetic Dermatology” This study found that valproic acid-loaded microemulsion formulations enhanced skin penetration pathways in guinea pigs compared to an aqueous solution, with composition elements like oil content and surfactant ratios significantly affecting drug delivery performance.
10 citations
,
January 2018 in “Dermatology online journal” This review describes the surgical and nonsurgical genital rejuvenation options for addressing hair, morphology, and vascular changes, noting increased interest but providing no new clinical findings.
February 2006 in “Inpharma Weekly”
16 citations
,
November 1992 in “Journal of International Medical Research” In this randomized study, ViviScal® significantly outperformed a fish extract in increasing non-vellus hair count and achieving clinical and histological improvement in young males with hereditary androgenic alopecia.
May 2025 in “Frontiers in Bioengineering and Biotechnology” In this study, the researchers reported that a novel exosome-based treatment, EX104, effectively reversed hair follicle miniaturization and promoted hair growth in a mouse model of androgenetic alopecia, showing results comparable to minoxidil and surpassing it in stimulating capillary growth and follicular proliferation.
January 2025 in “The Pharma Innovation” This review discusses how nanospanlastics, a type of ultra deformable vesicular nanocarrier, could enhance glaucoma management by improving the delivery and effectiveness of intraocular pressure-lowering agents, tackling adherence challenges, and advancing targeted therapies, according to the authors.
February 2026 in “Nano Research” This study developed a dissolvable microneedle system delivering specific molecules to remodel lymphatic networks and normalize metabolic processes, which accelerated hair growth and activated hair follicle stem cells in a mouse model of androgenetic alopecia.
April 2017 in “Australasian Journal of Dermatology” Different skin conditions show distinct types of vessel inflammation, a new quality of life index for vulval disease is reliable, a certain intrauterine system might be linked to chronic vaginal yeast infections, and oral minoxidil reduces hair loss in women.
February 2026 in “Libri Oncologici Croatian Journal of Oncology” The review found that imiquimod is a promising non-invasive treatment for HPV-related neoplasias, particularly effective for vulvar lesions, but notes that more research is needed to optimize its use.